sermorelin + GHK-Cu + BPC-157 [Best and safest combo for puberty?]

[dantehilly]

Running Sermorelin + GHK-Cu + BPC-157. They target different things, so here’s the jist of what each one is for:


Sermorelin — GH / IGF-1 / body composition


Sermorelin is a GHRH analogue. It binds to GHRH receptors in the pituitary and basically signals your body to release more of its own growth hormone. That increased GH can then increase downstream IGF-1 signaling.


Main targets:

• GH/IGF-1 pathway
• Body composition
• Protein/fat metabolism
• Recovery and tissue turnover

GHK-Cu — skin / collagen / hair


GHK-Cu is a copper peptide that’s mainly interesting for skin and tissue remodeling. It affects fibroblast activity, collagen production, extracellular-matrix remodeling, and other repair pathways.


Main targets:

• Collagen + elastin
• Skin quality
• Tissue remodeling/repair
• Hair/skin applications

BPC-157 — recovery / connective tissue


BPC-157 is mainly used with recovery in mind. It interacts with pathways involving nitric oxide, angiogenesis, fibroblasts, and tissue repair.


Main targets:

• Tendons/ligaments
• Muscle and connective-tissue recovery
• Blood-vessel formation
• General tissue repair

So basically:


Sermorelin = GH/body composition


GHK-Cu = skin/collagen


BPC-157 = recovery/connective tissue

Near perfect starting peptide combo
Relatively safe during puberty

 

[femboylover41]

Running Sermorelin + GHK-Cu + BPC-157. They target different things, so here’s the jist of what each one is for:


Sermorelin — GH / IGF-1 / body composition


Sermorelin is a GHRH analogue. It binds to GHRH receptors in the pituitary and basically signals your body to release more of its own growth hormone. That increased GH can then increase downstream IGF-1 signaling.


Main targets:

• GH/IGF-1 pathway
• Body composition
• Protein/fat metabolism
• Recovery and tissue turnover

GHK-Cu — skin / collagen / hair


GHK-Cu is a copper peptide that’s mainly interesting for skin and tissue remodeling. It affects fibroblast activity, collagen production, extracellular-matrix remodeling, and other repair pathways.


Main targets:

• Collagen + elastin
• Skin quality
• Tissue remodeling/repair
• Hair/skin applications

BPC-157 — recovery / connective tissue


BPC-157 is mainly used with recovery in mind. It interacts with pathways involving nitric oxide, angiogenesis, fibroblasts, and tissue repair.


Main targets:

• Tendons/ligaments
• Muscle and connective-tissue recovery
• Blood-vessel formation
• General tissue repair

So basically:


Sermorelin = GH/body composition


GHK-Cu = skin/collagen


BPC-157 = recovery/connective tissue

Near perfect starting peptide combo
Relatively safe during puberty

Its ok but all the peptides around gh production are cope there just dont do enough just wasting money at this point
Hope this helps

 

[dantehilly]

Its ok but all the peptides around gh production are cope there just dont do enough just wasting money at this point
Hope this helps

Not really

more gh = more chance of growth

 

[Paul.jnxy]

Running Sermorelin + GHK-Cu + BPC-157. They target different things, so here’s the jist of what each one is for:


Sermorelin — GH / IGF-1 / body composition


Sermorelin is a GHRH analogue. It binds to GHRH receptors in the pituitary and basically signals your body to release more of its own growth hormone. That increased GH can then increase downstream IGF-1 signaling.


Main targets:

• GH/IGF-1 pathway
• Body composition
• Protein/fat metabolism
• Recovery and tissue turnover

GHK-Cu — skin / collagen / hair


GHK-Cu is a copper peptide that’s mainly interesting for skin and tissue remodeling. It affects fibroblast activity, collagen production, extracellular-matrix remodeling, and other repair pathways.


Main targets:

• Collagen + elastin
• Skin quality
• Tissue remodeling/repair
• Hair/skin applications

BPC-157 — recovery / connective tissue


BPC-157 is mainly used with recovery in mind. It interacts with pathways involving nitric oxide, angiogenesis, fibroblasts, and tissue repair.


Main targets:

• Tendons/ligaments
• Muscle and connective-tissue recovery
• Blood-vessel formation
• General tissue repair

So basically:


Sermorelin = GH/body composition


GHK-Cu = skin/collagen


BPC-157 = recovery/connective tissue

Near perfect starting peptide combo
Relatively safe during puberty

This won't do shit for you JFL other then cope

Its ok but all the peptides around gh production are cope there just dont do enough just wasting money at this point
Hope this helps

Iqlet. They do, just at higher dosages and in synergy

Not really

more gh = more chance of growth

Holy fuck men. You are so uneducated. GH alone for height is cope. Do you think some seramoerlin with BBC167 and NHH-cu is gonna turn you into 6 foot 7 gigachad

All greys should die

 

[dantehilly]

This won't do shit for you JFL other then cope

Iqlet. They do, just at higher dosages and in synergy

Holy fuck men. You are so uneducated. GH alone for height is cope. Do you think some seramoerlin with BBC167 and NHH-cu is gonna turn you into 6 foot 7 gigachad

All greys should die

are you retarded look at the scientific evidence

it’s not cope nigga

you just a dumbfuck

 

[Paul.jnxy]

are you retarded look at the scientific evidence

it’s not cope nigga

you just a dumbfuck

 

[dantehilly]

nigga what

 

[Paul.jnxy]

nigga what

u are dumb as shit. keep coping boyo

 

[dantehilly]

u are dumb as shit. keep coping boyo

do your scientific research before you listen to these forums blindly

you lit just don’t wanna admit it

and look weak JFL

 

[Paul.jnxy]

do your scientific research before you listen to these forums blindly

you lit just don’t wanna admit it

and look weak JFL

lol. show me the studies

 

[dantehilly]

lol. show me the studies

Studies showing GH has a dose-response relationship with growth/height in children who still have growth potential:

Prepubertal children with growth hormone deficiency treated for four years with growth hormone experience dose-dependent increase in height, but not in the rate of puberty initiation - PubMed

rhGH, 50 and 100 μg/kg/day, induced greater growth than 25 μg/kg/day without altering the proportion of children starting puberty. The maximum approved dose for pubertal patients (100 μg/kg/day) is not required or recommended for prepubertal children with GHD.

pubmed.ncbi.nlm.nih.gov

Growth hormone dose-dependent pubertal growth: a randomized trial in short children with low growth hormone secretion - PubMed

Pubertal heightSDSgain and AHSDS were dose dependent, with greater growth being observed for the GH(67) than the GH(33) randomization group; however, there were no differences between the once- and twice-daily GH(67) regimens. © 2014 S. Karger AG, Basel.

pubmed.ncbi.nlm.nih.gov

Final height gain by GH therapy in children with idiopathic short stature is dose dependent - PubMed

Recombinant human GH therapy to children with idiopathic short stature (ISS) increases growth velocity, but its effect on final height (FH) is still uncertain. The aim of this study was to investigate the effect of recombinant human GH on FH of patients with ISS who were treated according to two...

pubmed.ncbi.nlm.nih.gov

[Insulin growth factor-I-based dosing of growth hormone therapy in children: a randomized, controlled study] - PubMed

Weight-based dosing of growth hormone (GH) is the standard of therapy in short children although insulin-like growth factor-I (IGF-I) is a major mediator of GH actions on growth. Objective: to test whether the IGF-I levels achieved during GH therapy are determinants of the growth responses to GH...

pubmed.ncbi.nlm.nih.gov

fucking retarded nigga jfl

 

[dantehilly]

lol. show me the studies

real quiet now nigga lmfao here’s some more

Studies showing increased linear growth/growth velocity from Sermorelin (GHRH 1-29):

Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity - PubMed

Short-term therapy with twice-daily s.c. injection of GHRHa (20 micrograms/kg) promoted linear growth in short children who were not GH-insufficient. The improved height velocity was sustained throughout the 12 months of treatment, followed by catch-down growth, and returned to pretreatment...

pubmed.ncbi.nlm.nih.gov

Growth during and after a trial of growth hormone releasing hormone 1-29 in children with idiopathic short stature or growth hormone neurosecretory dysfunction - PubMed

The growth promoting effects of once nightly subcutaneous injections of growth hormone releasing hormone (GHRH) 1-29 (30 microg/kg) for 6 months were studied in 16 slowly growing prepubertal children with idiopathic short stature (ISS; Group 1) and 8 similar children with growth hormone...

pubmed.ncbi.nlm.nih.gov

Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group - PubMed

The efficacy and safety of 1 yr of GH-releasing hormone [GHRH-(1-29)] therapy in GH-deficient children were determined. One hundred and ten previously untreated prepubertal GH-deficient children were treated for up to 1 yr in a multicenter, open label study with 30 micrograms/kg GHRH-(1-29)/day...

pubmed.ncbi.nlm.nih.gov

A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency - PubMed

In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months. There...

pubmed.ncbi.nlm.nih.gov

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency - PubMed

Sermorelin is a well tolerated analogue of GHRH which is suitable for use as a provocative test of growth hormone deficiency when given as a single intravenous 1 microg/kg bodyweight dose in conjunction with conventional tests. Limited data suggest that once daily subcutaneous sermorelin 30...

pubmed.ncbi.nlm.nih.gov

 

[Paul.jnxy]

real quiet now nigga lmfao here’s some more

Studies showing increased linear growth/growth velocity from Sermorelin (GHRH 1-29):

Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity - PubMed

Short-term therapy with twice-daily s.c. injection of GHRHa (20 micrograms/kg) promoted linear growth in short children who were not GH-insufficient. The improved height velocity was sustained throughout the 12 months of treatment, followed by catch-down growth, and returned to pretreatment...

pubmed.ncbi.nlm.nih.gov

Growth during and after a trial of growth hormone releasing hormone 1-29 in children with idiopathic short stature or growth hormone neurosecretory dysfunction - PubMed

The growth promoting effects of once nightly subcutaneous injections of growth hormone releasing hormone (GHRH) 1-29 (30 microg/kg) for 6 months were studied in 16 slowly growing prepubertal children with idiopathic short stature (ISS; Group 1) and 8 similar children with growth hormone...

pubmed.ncbi.nlm.nih.gov

Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group - PubMed

The efficacy and safety of 1 yr of GH-releasing hormone [GHRH-(1-29)] therapy in GH-deficient children were determined. One hundred and ten previously untreated prepubertal GH-deficient children were treated for up to 1 yr in a multicenter, open label study with 30 micrograms/kg GHRH-(1-29)/day...

pubmed.ncbi.nlm.nih.gov

A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency - PubMed

In this study, 60 patients with proven growth hormone deficiency (GHD) of hypothalamic origin were randomized into three equal groups, and received growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2), 30 or 60 micrograms/kg/day, or growth hormone (GH), 0.1 IU/kg/day, for 6 months. There...

pubmed.ncbi.nlm.nih.gov

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency - PubMed

Sermorelin is a well tolerated analogue of GHRH which is suitable for use as a provocative test of growth hormone deficiency when given as a single intravenous 1 microg/kg bodyweight dose in conjunction with conventional tests. Limited data suggest that once daily subcutaneous sermorelin 30...

pubmed.ncbi.nlm.nih.gov

Will reply tmrw it’s getting late. Bro just asked ChatGPT. Anyways will debunk your shitty studies. GH almost never increases FAH you retard.

 

[dantehilly]

Will reply tmrw it’s getting late. Bro just asked ChatGPT. Anyways will debunk your shitty studies. GH almost never increases FAH you retard.

you obviously wouldn’t know being 5’9

 

[Paul.jnxy]

you obviously wouldn’t know being 5’9

You are so fucking retarded nigha. Im barely 15 + I use non cope methods to maximise my growth. Height is also almost purely genetic you fucktard faggot.

 

[jeremyy]

 

[Theaveragegrey#2]

View attachment 5502638

who tf is that LOOOL

 

[dantehilly]

You are so fucking retarded nigha. Im barely 15 + I use non cope methods to maximise my growth. Height is also almost purely genetic you fucktard faggot.

well i’m taller then you at 14, i’m 5’11 so keep staying mad

JFL

 

[Paul.jnxy]

well i’m taller then you at 14, i’m 5’11 so keep staying mad

Wow, flexing the better hand. + ur plates ight be fused and then its over for u lol

JFL

Bought VIP with the shittiest post to rep i have ever seen